Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium breve M-16V
- Development stage
- Phase 4
- Lead developer
- Morinaga Milk Industry
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium breve M-16V is a well-researched probiotic strain of bacteria developed and manufactured by Morinaga Milk Industry Co., Ltd. [2, 6, 11] It is widely used, particularly for infants (including preterm and low-birth-weight infants), to support healthy development. [1, 2, 9, 10] The strain has been shown to promote the colonization of beneficial bacteria in the gut, improve gut barrier function, and modulate the immune system. [1, 8, 9] B. breve M-16V is studied for its potential to prevent or alleviate allergic diseases, such as atopic dermatitis, and necrotizing enterocolitis (NEC) in high-risk infants. [1, 5, 7, 10] Its mechanism involves balancing the immune response, often by suppressing Th2-mediated allergic reactions and promoting anti-inflammatory pathways. [2, 5, 8] It is commonly incorporated into infant formulas and dietary supplements and has received GRAS (Generally Recognized as Safe) status from the US FDA for use in these products. [2, 9]
- Brand names
- Morinaga Bifidus M-16V
- Other names
- B. breve M-16VBifidobacterium breve strain M-16V
Beyond the preview
Go deeper on bifidobacterium breve M-16V.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium breve M-16V.